Boehringer Ingelheim Prepares a New Drug Against Obesity

Boehringer Ingelheim prepares the launch of its new drug against obesity. The pharmaceutical company will launch phase III of its medication, after the positive results achieved in phase II in weight loss after 46 weeks of treatment for patients with this disease, according to a statement issued by the company.

The medicine called Survodutide has been developed together with the biotech company Zealand Pharma. With this trial, both companies are looking for their niche market with a potential value of $100 trillion for treatments against obesity.

Survodutide works by mimicking a gut hormone called glucagon-like peptide-1, which suppresses appetite and helps break down fat. Also, this same drug is being tested in patients who have a fatty liver, called non-alcoholic steatohepatitis.

If you want to read more details about the new drug against obesity that is currently tested by Boehringer Ingelheim, download for free our companion app. The Born2Invest mobile app keeps its readers up to date with the most important business news of the day.

Boehringer Ingelheim has developed this new obesity drug with Zealand Pharma

Recently, the German pharmaceutical company allocated €13 million to the digitization of its technology facility in Sant Cugat del Vallès (Barcelona). In addition, the pharmaceutical intends to expand this center by 10% throughout this year.

Its center in Barcelona is one of the largest that the pharmaceutical company has after its headquarters in the United States. In addition, it houses the cyber intelligence and security operations center, which is in charge of identifying vulnerabilities and possible cyberattacks in order to protect and prepare the company against this type of event.

This technological facility was inaugurated ten years ago with more than one hundred workers, becoming one of the first global IT service infrastructures in the Barcelona area. Currently, the workforce is approximately three hundred people, and provides services to more than 50,000 users.

The technology hub also incorporates the network operation center, the factory automation center of excellence, and the Salesforce center of excellence, among others. The new industry 4.0 technologies are also manufactured from this plant to achieve the most advanced level of automation in drug production plants on a global scale.

The pharmaceutical company Boehringer Ingelheim was founded in 1885 by Albert Boehringer in Ingelheim am Rhein (Germany). In 1952 the company’s productive, administrative, and commercial activity began in the Spanish market. Currently, the company produces in the country at its plants in Malgrat de Mar and Sant Cugat del Vallès (Barcelona).

__

(Featured image by TaniaDimas via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.